Higher Thinking are raising funds with a goal to support research which will assist in either slowing or preventing progression from low to high grade tumours. Funds raised will be directed towards an exciting project led by Dr Leonie Quinn.
Dr Quinn is conducting a study looking at drug targets for oligodendroglioma, the second most common primary brain cancer in adults. While median survival for this particular type of brain cancer is around 15 years, much longer than the most common adult brain cancer – glioblastoma, which sees people survive an average of 15 months, people oligodendroglioma often suffer from severe seizures and neurological deficits after treatment and as their tumour progresses.
The project aims to identify new prognostic markers within these types of tumours, and subsequently investigate drug therapies for specific tumours based on their molecular signature. This will enable more individualised treatments, which is critical to improving survival and quality of life for patients diagnosed with the disease.
23 days left
for all the latest research, events and fundraising news